Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C. Grunfeld, D.P. Kotler, R. Hamadeh, A. Tierney, J. Wang, R.N. Pierson.
Hypertriglyceridemia in the acquired immunodeficiency syndrome.
Am J Med, 86 (1989), pp. 27-31
[2.]
C. Grunfeld, K. Feingold.
Metabolic disturbances and wasting in the acquired immunodeficiency syndrome.
N Engl J Med, 327 (1992), pp. 329-337
[3.]
R. Muga, J. Tor, C. Rey-Joly, A. Pardo, P. Llobet, M. Foz.
Dislipemia e infección por VIH-1 en adictos a drogas intravenosas.
Med Clin (Barc, 100 (1993), pp. 161-163
[4.]
F.J. Palella, K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, et al.
Declining morbidity and mortality among patients with advanced HIV infection.
N Engl J Med, 338 (1998), pp. 853-860
[5.]
G. Ippolito, V. Galati, D. Serraino, E. Girardi.
The changing picture of the HIV/AIDS epidemic.
Ann N Y Acad Sci, 946 (2001), pp. 1-12
[6.]
A. Carr, K. Samaras, S. Burton, M. Law, J. Freund, D.J. Chisholm, et al.
A syndrome of peripheral lipodystrophy hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
AIDS, 12 (1998), pp. 51-58
[7.]
K.D. Miller, E. Jones, J.A. Yanovski, R. Shankar, I. Feuerstein, J. Falloon.
Visceral abdominal-fat accumulation associated with use of indinavir.
Lancet, 351 (1998), pp. 871-875
[8.]
T. Aldeen, C. Wells, P. Hay, F. Davidson, R. Lau.
Lipodystrophy associated with nevirapine-containing antiretroviral therapies.
AIDS, 13 (1999), pp. 865-867
[9.]
T. Saint-Marc, M. Partisani, I. Poizot-Martin, F. Bruno, O. Rouviere, J.M. Lang, et al.
A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long term nucleoside analogue therapy.
AIDS, 13 (1999), pp. 1659-1667
[10.]
A. Carr, K. Samaras, D.J. Chisholm, D.A. Cooper.
Pathogenesis of HIV-1 protease-inhibitor asssociated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
Lancet, 351 (1998), pp. 1881-1883
[11.]
K. Samaras, P.J. Kelly, M.N. Chiano, T.D. Spector, L.V. Campbell.
Genetic and environmental influences on total-body and central abdominal fat: the effect of physical activity in female twins.
Ann Intern Med, 130 (1999), pp. 873-882
[12.]
M. Clerici, M. Galli, S. Bosis, C. Gervasoni, M. Moroni, G. Norbiato.
Immunoendocrinologic abnormalities in human immunodeficiency virus infection.
Ann N Y Acad Sci, 917 (2000), pp. 956-961
[13.]
E. Ledru, N. Christeff, O. Patey, P. de Truchis, J.C. Melchior, M.L. Gougeon.
Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome.
Blood, 95 (2000), pp. 3191-3198
[14.]
R. Wurtz, S. Ceaser.
Adipose redistribution in human immunodeficiency virus-seropositive patients: association with CD4 response.
Clin Infect Dis, 31 (2000), pp. 1497-1498
[15.]
D. Periard, A. Telenti, P. Sudre, J.J. Cheseaux, P. Halfon, M.J. Reymond, et al.
Atherogenic dyslipidemias in HIV-infected individuals treated with protease inhibitors. Swiss HIV Cohort Study.
Circulation, 100 (1999), pp. 700-705
[16.]
F. Bonnet, M. Saves, C. Droz, E. Peuchant, G. Chene, J. Beylot, et al.
Increase of atherogenic plasma profile in HIV-patients treated with protease inhibitor-containing regimens.
J Acquir Immune Defic Syndr, 25 (2000), pp. 199-200
[17.]
G.J. Moyle, C. Baldwin.
Lipid elevations during non-nucleoside RTI (NNRTI) therapy: a cross-sectional analysis.
Antiviral Ther, 4 (1999), pp. 58
[18.]
R. Polo, J. Verdejo, S. Martinez-Rodríguez, P. Madrigal, M. González-Munoz.
Lipoatrophy, fat accumulation, and mixed syndrome in protease inhibitor-naive HIV-infected patients.
J Acquir Immune Defic Syndr, 25 (2000), pp. 284-286
[19.]
R. Walli, O. Herfort, G.M. Michl, T. Demant, H. Jager, C. Dieterle, et al.
Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients.
AIDS, 12 (1998), pp. 167-173
[20.]
E. Martínez, I. Conget, L. Lozano, R. Casamitjana, J.M. Gatell.
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.
AIDS, 13 (1999), pp. 805-810
[21.]
National Cholesterol Education Program. Third report of the National Cholesterol Education Program on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA, 285 (2001), pp. 2486-2497
[22.]
M. Egger, C. Junghans, N. Friis-Moller, J.D. Lundgren.
Highly active antiretroviral therapy and coronary heart disease: the need for perspective.
AIDS, 15 (2001), pp. 193-201
[23.]
M. Galli, A.L. Ridolfo, C. Gervasoni.
Cardiovascular disease risk factors in HIV-infected patients in the HAART era.
Ann N Y Acad Sci, 946 (2001), pp. 1-12
[24.]
C. Hadigan, J.B. Meigs, C. Corcoran, P. Rietschel, S. Piecuch, N. Basgoz, et al.
Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.
Clin Infect Dis, 32 (2001), pp. 130-139
[25.]
H. Valdez, T.K. Chowdhry, R. Asaad, I.J. Woolley, T. Davis, R. Davidson, et al.
Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999.
Clin Infect Dis, 32 (2001), pp. 1487-1493
[26.]
G. Behrens, H. Schmidt, D. Meyer, M. Stoll, R.E. Schmidt.
Vascular complications associated with use of HIV protease inhibitors.
Lancet, 351 (1998), pp. 1958
[27.]
K. Henry, H. Melroe, J. Huebsch, J. Hermundson, C. Levine, L. Swensen, et al.
Severe premature coronary artery disease with protease inhibitors.
Lancet, 351 (1998), pp. 1328
[28.]
M. Karmochkine, G. Raguin.
Severe coronary artery disease in a young HIV infected man with no cardiovascular risk factors who was treated with indinavir.
AIDS, 12 (1998), pp. 2499
[29.]
T.E. Flynn, L.A. Bricker.
Myocardial infarction in HIV infected men receiving protease inhibitors.
Ann Intern Med, 131 (1999), pp. 548
[30.]
K. Koppel, G. Bratt, J. Rajs.
Sudden cardiac death in a patient on 2 years of highly active antiretroviral treatment: a case report.
AIDS, 13 (1999), pp. 1993-1994
[31.]
A.C. Friedl, C.H. Attenhofer, C. Schalcher, F.W. Amann, M. Flepp, R. Jenni, et al.
Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy.
AIDS, 14 (2000), pp. 2790-2792
[32.]
J.D. Passalaris, K.A. Sepkowitz, M.J. Glesby.
Coronary artery disease and human immunodeficiency virus.
Clin Infect Dis, 31 (2000), pp. 787-797
[33.]
P. Maggi, G. Serio, G. Epifani, G. Fiorentino, A. Saracino, C. Fico, et al.
Premature lesions of the carotid vessels in HIV-1 infected patients treated with protease inhibitors.
AIDS, 14 (2000), pp. 123-128
[34.]
M. Depairon, S. Chessex, P. Sudre, N. Rodondi, N. Doser, J.P. Chave, et al.
Swiss HIV Cohort Study. Premature atherosclerosis in HIVinfected individuals: focus on protease inhibitor therapy.
AIDS, 15 (2001), pp. 329-334
[35.]
M.H. David, R. Hornung, C.J. Fichtenbaum.
Ischemic cardiovascular disease in persons with immunodeficiency virus infection.
Clin Infect Dis, 34 (2002), pp. 98-102
[36.]
V. Rickerts, H. Brodt, S. Staszewski, W. Stille.
Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study.
Eur J Med Res, 5 (2000), pp. 329-333
[37.]
A. Jutte, A. Schwenk, C. Franzen, K. Romer, F. Diet, V. Diehl, et al.
Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?.
AIDS, 13 (1999), pp. 1796-1797
[38.]
On line: www.cphiv.dk/dad
[39.]
Van Leth F, Friis-Moller N, Weber R, D’Arminio Monforte A, Kirk O, Thiebaut R, et al. Distinguishable lipid profiles between PI and NNRTI therapy may carry different risk of cardiovascular disease. 9th Conference on Retroviruses and Opportunistic Infections [resumen 34]. Seattle, marzo de 2002
[40.]
Holmberg S, Moorman A, Tong T, Ward D, Wood K, Greenberg AE, et al. Protease inhibitor use and adverse cardiovascular outcomes in ambulatory HIV patients. 9th Conference on Retroviruses and Opportunistic Infections [resumen 698]. Seattle, marzo de 2002
[41.]
M. Egger, G.D. Smith, D. Pfluger, E. Altpeter, P.C. Elwood.
Triglyceride as a risk factor for ischemic heart disease in British men: effect of adjusting for measurement error.
Atherosclerosis, 143 (1999), pp. 275-284
[42.]
M.P. Dube, D. Sprecher, W.K. Henry, J.A. Aberg, F.J. Torriani, H.N. Hodis, et al.
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
Clin Infect Dis, 31 (2000), pp. 1216-1224
[43.]
National Cholesterol Education Program. Second report of the National Cholesterol Education Program on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel II).
Circulation, 89 (1994), pp. 1329-1445
[44.]
Martínez E, Fernández-Miranda C, Conget I, Moreno S, Santamaría JM, Boix V, et al. Actitud ante las alteraciones metabólicas y de distribución de la grasa corporal en pacientes infectados por el virus de la inmunodeficiencia humana que reciben tratamiento antirretroviral. Documento de consenso de GESIDA/ Plan Nacional sobre el sida. Diciembre de 2001. Disponible en: www.msc.es/sida/publicaciones
[45.]
L. Masana, E. Negredo, J. Pedro-Botet, B. Clotet.
Guía del manejo de las dislipemias en pacientes infectados por el VIH.
Edipharma, (2002), pp. 1-77
Copyright © 2002. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.